301 related articles for article (PubMed ID: 21266595)
1. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
2. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
Ghassabian S; Rawling T; Zhou F; Doddareddy MR; Tattam BN; Hibbs DE; Edwards RJ; Cui PH; Murray M
Biochem Pharmacol; 2012 Jul; 84(2):215-23. PubMed ID: 22513143
[TBL] [Abstract][Full Text] [Related]
3. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Sulkes A
Isr Med Assoc J; 2010 Oct; 12(10):628-32. PubMed ID: 21090521
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
Shibayama Y; Nakano K; Maeda H; Taguchi M; Ikeda R; Sugawara M; Iseki K; Takeda Y; Yamada K
Biol Pharm Bull; 2011; 34(3):433-5. PubMed ID: 21372398
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
6. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
8. Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Zhuang X; Zhang T; Yue S; Wang J; Luo H; Zhang Y; Li Z; Che J; Yang H; Li H; Zhu M; Lu C
Biochem Pharmacol; 2016 Dec; 121():67-77. PubMed ID: 27666601
[TBL] [Abstract][Full Text] [Related]
9. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
11. Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5.
Okada Y; Murayama N; Yanagida C; Shimizu M; Guengerich FP; Yamazaki H
Drug Metab Dispos; 2009 Jan; 37(1):18-23. PubMed ID: 18948377
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4.
Ghassabian S; Gillani TB; Rawling T; Crettol S; Nair PC; Murray M
AAPS J; 2019 Jan; 21(2):15. PubMed ID: 30627802
[TBL] [Abstract][Full Text] [Related]
13. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.
Krusch M; Salih J; Schlicke M; Baessler T; Kampa KM; Mayer F; Salih HR
J Immunol; 2009 Dec; 183(12):8286-94. PubMed ID: 20007592
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5.
Li X; Song X; Kamenecka TM; Cameron MD
Drug Metab Dispos; 2012 Sep; 40(9):1803-9. PubMed ID: 22696420
[TBL] [Abstract][Full Text] [Related]
17. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
Huang Y; Wang Y; Li Y; Guo K; He Y
J Cancer Res Clin Oncol; 2011 May; 137(5):829-37. PubMed ID: 20809412
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects.
McDonald MG; Tian DD; Thummel KE; Paine MF; Rettie AE
Drug Metab Dispos; 2020 Oct; 48(10):1018-1027. PubMed ID: 32591416
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and sunitinib.
Kim A; Balis FM; Widemann BC
Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
[No Abstract] [Full Text] [Related]
20. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
